Naloxone is an opioid antagonist medication used to reverse opioid effects, especially respiratory depression during overdose. It is available in intranasal, intramuscular, and intravenous forms, with rapid onset in emergency use. Naloxone was approved for opioid overdose in the United States in 1971.
The FDA granted Breakthrough Device Designation to TOBY Inc.'s urine-based Alzheimer's diagnostic test and Instanosis Inc.'s Xylazine Rapid Test (Urine), accelerating development of both non-invasive diagnostic technologies.
Eli Lilly has launched two Phase 2 trials for brenipatide (LY3537031): RENEW-Op-1 for opioid use disorder and RENEW-Scz-1 for schizophrenia. Both are randomized, double-blind, placebo-controlled studies that are not yet recruiting as of February 2026.
Knox County officials are seeking restrictions on cychlorphine after the synthetic opioid was detected in 41 overdose deaths in and around Knox County. The drug is described as extremely potent, not detectable through most test kits, and may require repeated naloxone doses in an overdose.
Tennessee has implemented comprehensive pharmacist scope-of-practice expansion allowing independent prescribing, testing, and treatment for select conditions. The legislation enables pharmacists to prescribe medications including antivirals, contraceptives, and naloxone without collaborative agreements. This expansion aims to improve healthcare access, particularly in rural areas with provider shortages.
U.S. overdose deaths declined 19% year-over-year to 72,108 for the 12 months ending September 2025, but the drug market is evolving with dangerous polydrug cocktails like "pink cocaine" and "rhino tranq" that are harder to detect and reverse. These synthetic blends combine fentanyl with stimulants, sedatives, and veterinary tranquilizers, creating new public health challenges as naloxone becomes less effective against complex overdoses.
British Columbia recorded 1,826 unregulated drug toxicity deaths in 2025, a 21% decrease from 2024. New research links the decline to decreasing fentanyl concentrations in the illicit drug supply, though nearly five people continue to die daily.
Eli Lilly launched the monthly Zepbound KwikPen for obesity treatment and initiated a Phase 2 trial for opioid use disorder, while Gilead Sciences agreed to acquire Arcellx for $7.8 billion to expand its cell therapy portfolio.
Emergent BioSolutions received FDA approval on Feb. 12, 2026, for 6-count and 24-count multipack configurations of over-the-counter NARCAN Nasal Spray, designed to meet the needs of partners distributing higher volumes of naloxone to community programs.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05528848 |
Multi-System Analysis of Opioid Receptor Binding |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT05490134 |
RM1 Project 1 - tAN Naloxone |
RECRUITING | EARLY_PHASE1 |
| NCT05360030 |
Mechanism of Analgesic Effect on Prolonged Continuous Theta Burst Stimulation |
COMPLETED | NA |
| NCT05142267 |
Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms |
RECRUITING | NA |
| NCT05114460 |
Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal |
TERMINATED | PHASE2 |
| NCT05072249 |
European Cohort Study of the Effectiveness of Take Home Naloxone |
UNKNOWN | |
| NCT04975347 |
Opioid Antagonism in Individuals Ascertained Through the Partners HealthCare Biobank |
COMPLETED | PHASE1 |
| NCT04975334 |
Opioid Antagonism in Hypogonadotropic Hypogonadism |
COMPLETED | PHASE1 |
| NCT04851301 |
Neural Mechanisms of Immersive Virtual Reality in Chronic Pain |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT04744883 |
Efficacy of Spinal Manipulation Therapy or Mindfulness-based Reduction Therapy on Patients With Chronic Low Back Pain |
ACTIVE_NOT_RECRUITING | EARLY_PHASE1 |
